The Silent Threat: Why Infections Haunt Bone Marrow Failure in Myelodysplastic Syndromes

Exploring the epidemiology and risk factors for infections in MDS patients

Article Navigation

Introduction: The Hidden Epidemic in Blood Disorders

Myelodysplastic syndromes (MDS) represent a group of insidious bone marrow disorders where the body's blood cell factory malfunctions. Patients produce poorly formed or dysfunctional blood cells, leading to fatigue, bleeding, and a crippling vulnerability to infections 6 . While often overshadowed by leukemia risk, infections are a leading cause of suffering and death in MDS.

Global MDS/MPN Cases

Affecting over 341,000 people annually, with incidence doubling since 1990 due to aging populations and improved diagnostics 4 5 .

Infection Risk

For these patients, a simple cold can escalate into life-threatening pneumonia.

Why MDS Breeds Infection: Beyond Simple Neutropenia

The Obvious Culprit: Neutropenia
  • ~50% of newly diagnosed MDS patients have low neutrophil counts 3
  • Rises to 70-80% in high-risk MDS
  • 15-20% risk even in lower-risk patients
Stealth Saboteurs: Neutrophil Dysfunction

Neutrophils in MDS aren't just scarce; they're defective with multiple impairments:

  • Phagocytosis Failure: Inability to "eat" pathogens 3
  • Oxidative Burst Defects: Reduced bacteria-killing oxygen radicals 3
  • Migration Errors: Faulty surface proteins (CD11b, LFA1) 3
  • Granule Deficiencies: Depleted antimicrobial enzymes 3

Broken Immunity: Beyond Neutrophils

T-cell Imbalance

Shifts in helper T-cell subtypes (TH1/TH2) weaken pathogen surveillance 3

B-cell Chaos

Hypergammaglobulinemia (39%) or hypogammaglobulinemia (8%) disrupt antibody production 3

Iron Overload

Repeated transfusions increase serum iron, which bacteria exploit 3

In-Depth Look: The European MDS Registry Breakthrough

The Experiment: Tracking Infections in 2,552 Patients

A landmark 2024 study analyzed lower-risk MDS patients across 17 countries using the European MDS Registry 1 . Its goal: Identify who gets infections and why.

Methodology: Step-by-Step Surveillance
Cohort Selection

2,552 newly diagnosed LR-MDS patients (IPSS-R low/intermediate risk)

Data Collection

Baseline labs, treatments, comorbidities

Outcome Tracking

Infections (type, severity) within 1 year of diagnosis

Statistical Analysis

Multivariable logistic regression to isolate independent risk factors

Results and Analysis: Who Is Most Vulnerable?

Table 1: Infection Prevalence & Impact
Metric Value
Infection prevalence 7.6% (1 in 13 patients)
Deaths due to infections 24.6% of all deaths
Most common infection Pneumonia (40% fatal cases)
1-year survival difference Significant (P = 0.007)
Data source: European MDS Registry 1 2
Table 2: Independent Risk Factors
Risk Factor Odds Ratio
Hemoglobin <8 g/dL 3.1x
Platelet count <50 × 10⁹/L 2.8x
ANC <0.8 × 10⁹/L 2.5x
Intermediate/Poor cytogenetics 2.2x
Transfusion dependence 1.9x
Key Findings
  • Baseline Cytopenias Are Deadly: The triad of severe anemia, thrombocytopenia, and neutropenia predicted >80% of infections.
  • Transfusions Amplify Risk: Iron overload from transfusions independently fueled infections.
  • Timing Matters: 68% of infections occurred within 6 months of diagnosis 1 .

Global Burden: The Rising Tide of MDS Infections

Projected MDS/MPN Cases

457,320
by 2045

With infections contributing significantly to 82,047 deaths annually 4 5 .

Demographic Patterns
  • Gender Gap: Males bear 60% of the burden 5
  • Regional Disparities: High-SDI countries have highest incidence, but low-middle-SDI regions face fastest growth 5

Prevention and Hope: Protecting the Vulnerable

Risk Stratification

Using IPSS-M scores + cytopenias (Hb <8 g/dL, platelets <50 × 10⁹/L) to flag high-risk patients 1 .

Proactive Monitoring
  • Weekly CBCs for neutropenic patients
  • Lung CT scans for high-risk patients 2
Emerging Therapies
  • Luspatercept for ring sideroblast MDS
  • Stem Cell Transplants for fit patients 5
Infection Prophylaxis
  • Antibacterial/Antifungal drugs for ANC <0.5 × 10⁹/L
  • Vaccinations against Streptococcus pneumoniae
  • Influenza vaccines
  • Regular ferritin monitoring 3

Conclusion: Turning the Tide Against an Invisible Foe

Infections in MDS are a complex cascade of failing blood cells, broken immunity, and environmental triggers. The European Registry study underscores that one in four MDS deaths stems from preventable infections—often in "lower-risk" patients 1 . As global cases surge, precision medicine offers hope: genetic profiling to identify vulnerable patients, targeted therapies to correct cytopenias, and vigilant monitoring during high-risk windows.

For patients and families: Connect with support communities like the Mayo Clinic's Blood Cancers & Disorders group for real-time advice and shared experiences 6 .

References